Shenling Guchang prescription ameliorates intestinal barrier inflammation in gestational diabetes rats <i>via</i> TLR4/NF-κB pathway DOI Open Access
Manling Li, Lisha Li,

Xingman Liu

et al.

Drug Discoveries & Therapeutics, Journal Year: 2024, Volume and Issue: 18(6), P. 343 - 352

Published: Dec. 11, 2024

Gestational diabetes mellitus (GDM) is linked to a greater risk of various maternal and fetal complications, including the possibility long-term metabolic issues in offspring. Our initial research suggests that Traditional Chinese Medicine formula, Shenling Guchang prescription (SLGP), may have an impact on gut microbiota. However, specific mechanisms through which it affects intestinal barrier inflammation GDM are still not fully understood. This study explored SLGP's GDM. Firstly, network pharmacology predicted key bioactive constituents targeting toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB), guiding experimental design. Subsequently, pregnant female rats were induced with intraperitoneal streptozotocin injection then divided into control, model, metformin, SLGP treatment groups. Blood samples collected for ELISA analysis measure levels inflammatory markers, tissues examined histologically using hematoxylin-eosin (HE) staining, western blot was conducted evaluate TLR4 NF-κB expression. Relative control rats, model group animals exhibited significant increases markers (IL-1β, IL-6, TNF-α, TGF-β, CRP), as well enhanced p-NF-κB p65 expression, along histopathological changes. Treatment notably reduced protein expression colonic tissue leading decrease damage. Overall, found modulate TLR4/NF-κB pathway, resulting enhancements insulin resistance reduction responses thereby providing protection intestines. demonstrates potential therapeutic effectiveness addressing

Language: Английский

Organ-on-a-chip: quo vademus? Applications and regulatory status DOI Creative Commons
Maria Mendes, Ana Sofia Morais,

A Carlos

et al.

Colloids and Surfaces B Biointerfaces, Journal Year: 2025, Volume and Issue: 249, P. 114507 - 114507

Published: Jan. 8, 2025

Organ-on-a-chip systems, also referred to as microphysiological systems (MPS), represent an advance in bioengineering microsystems designed mimic key aspects of human organ physiology and function. Drawing inspiration from the intricate hierarchical architecture body, these innovative platforms have emerged invaluable vitro tools with wide-ranging applications drug discovery development, well enhancing our understanding disease physiology. The facility replicate tissues within physiologically relevant three-dimensional multicellular environments empowers organ-on-a-chip versatility throughout different stages development process. Moreover, can be tailored specific states, facilitating investigation progression, responses, potential therapeutic interventions. In particular, they demonstrate, early-phase pre-clinical studies, safety toxicity profiles compounds. Furthermore, play a pivotal role evaluation efficacy modeling diseases. One most promising prospects technology is simulate pathophysiology subpopulations even individual patients, thereby being used personalized medicine. By mimicking physiological responses diverse patient groups, hold promise revolutionizing strategies, guiding them towards intervention unique needs each patient. This review presents status evolution microfluidic that facilitated transition cells organs recreated on chips some opportunities offered by technology. Additionally, current future perspectives challenges this still faces are discussed.

Language: Английский

Citations

1
Precision Psychobiotics for Gut–Brain Axis Health: Advancing the Discovery Pipelines to Deliver Mechanistic Pathways and Proven Health Efficacy DOI Creative Commons
Rebecca F. Slykerman, Naomi Davies, Klára Vlčková

et al.

Microbial Biotechnology, Journal Year: 2025, Volume and Issue: 18(1)

Published: Jan. 1, 2025

ABSTRACT Advancing microbiome–gut–brain axis science requires systematic, rational and translational approaches to bridge the critical knowledge gaps currently preventing full exploitation of gut microbiome as a tractable therapeutic target for gastrointestinal, mental brain health. Current research is still marked by many open questions that undermine widespread application humans. For example, lack mechanistic understanding probiotic effects means it remains unclear why even apparently closely related strains exhibit different in vivo. live microbial psychobiotics, consensus on their adjunct treatments conventional neuromodulators, use unmedicated populations or at‐risk cohorts with sub‐clinical symptomatology warranted. This missing information both sides equation when treating central nervous system (CNS) conditions makes psychobiotic challenging, especially compared other pharmaceutical functional food approaches. Expediting transition from positive preclinical data proven benefits humans includes interpreting promises pitfalls animal behavioural assays, well navigating mechanism‐informed decision making select right microbe(s) job. In this review, we consider how these decisions can be supported light accrued range clinical studies across healthy, pathological study populations, where specific have been evaluated context gastrointestinal physiology, function behaviour. Examples successful, partial unsuccessful translation bench bedside are considered. We also discuss developments silico analyses enhanced our moved towards pinpointing host–microbe interactions most important optimal gut–brain function. Combining assays vitro ex vivo domains incorporating model organisms prime discovery pipelines promising rationally selected candidates.

Language: Английский

Citations

1
Peyer’s Patch: Possible target for modulating the Gut-Brain-Axis through microbiota DOI
Reza Asgari, Mohammad Amin Bazzazan,

Ashkan Karimi Jirandehi

et al.

Cellular Immunology, Journal Year: 2024, Volume and Issue: 401-402, P. 104844 - 104844

Published: June 18, 2024

Language: Английский

Citations

4
The Future Exploring of Gut Microbiome-Immunity Interactions: From In Vivo/Vitro Models to In Silico Innovations DOI Creative Commons
Sara Bertorello,

Francesco Cei,

Dorian Fink

et al.

Microorganisms, Journal Year: 2024, Volume and Issue: 12(9), P. 1828 - 1828

Published: Sept. 4, 2024

Investigating the complex interactions between microbiota and immunity is crucial for a fruitful understanding progress of human health disease. This review assesses animal models, next-generation in vitro silico approaches that are used to decipher microbiome-immunity axis, evaluating their strengths limitations. While models provide comprehensive biological context, they also raise ethical practical concerns. Conversely, modern reduce involvement but require specific costs materials. When considering environmental impact these emerge as promising resource reduction, robust experimental validation ongoing refinement. Their potential significant, paving way more sustainable future research.

Language: Английский

Citations

1
The Future of Biohybrid Regenerative Bioelectronics DOI Creative Commons
Alejandro Carnicer‐Lombarte, George G. Malliaras, Damiano G. Barone

et al.

Advanced Materials, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 20, 2024

Abstract Biohybrid regenerative bioelectronics are an emerging technology combining implantable devices with cell transplantation. Once implanted, biohybrid integrate host tissue. The combination of transplant and device provides avenue to both replace damaged or dysfunctional tissue, monitor control its function high precision. While early challenges in the fusion biological technological components limited development technologies, progress field has resulted a rapidly increasing number applications. In this perspective great potential for delivery therapy is discussed, including recent research new directions. Then barriers discussed that will need be addressed unlock full devices.

Language: Английский

Citations

1
In situ monitoring of neurotransmitters using a polymer nanostructured electrochemical sensing microchip DOI

Md Fazlay Rubby,

Catherine Fonder, Sajid Uchayash

et al.

Microchemical Journal, Journal Year: 2024, Volume and Issue: 204, P. 111159 - 111159

Published: July 9, 2024

Language: Английский

Citations

1
Functional Assessment of a Bioprinted Immuno‐Mimetic Peyer's Patch Recapitulating Gut‐Associated Lymphoid Tissue DOI
J.-S. Park, Gihyun Lee, Je‐Kyun Park

et al.

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 1, 2024

Gut immune models have attracted much interest in better understanding the microbiome human gastrointestinal tract. The gut-associated lymphoid tissue (GALT) has complex structures that interact with microorganisms, including intestinal monolayer as a physiological barrier and Peyer's patch (PP) involved system. Although essential for studying GALT interactions, current research often uses simplified only recapitulate some components. In this study, is recapitulated to consider morphology function of lymphocyte-containing PP beneath analyze interaction. Using bioprinting technique, dome-shaped structure array fabricated, epithelial cells are cocultured form monolayer. developed model shows stable cell differentiation on hydrogel while exhibiting durability against lipopolysaccharides. It also exhibits increased responsiveness Escherichia coli, indicated by elevated nitric oxide levels. addition, underscores critical role maintaining bacterial coexistence facilitating defense foreign antigens through secretion immunoglobulin A lymphocyte spheroids. proposed expected provide significant insights into gut-immune system complexity microbiome.

Language: Английский

Citations

0
Shenling Guchang prescription ameliorates intestinal barrier inflammation in gestational diabetes rats <i>via</i> TLR4/NF-κB pathway DOI Open Access
Manling Li, Lisha Li,

Xingman Liu

et al.

Drug Discoveries & Therapeutics, Journal Year: 2024, Volume and Issue: 18(6), P. 343 - 352

Published: Dec. 11, 2024

Gestational diabetes mellitus (GDM) is linked to a greater risk of various maternal and fetal complications, including the possibility long-term metabolic issues in offspring. Our initial research suggests that Traditional Chinese Medicine formula, Shenling Guchang prescription (SLGP), may have an impact on gut microbiota. However, specific mechanisms through which it affects intestinal barrier inflammation GDM are still not fully understood. This study explored SLGP's GDM. Firstly, network pharmacology predicted key bioactive constituents targeting toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB), guiding experimental design. Subsequently, pregnant female rats were induced with intraperitoneal streptozotocin injection then divided into control, model, metformin, SLGP treatment groups. Blood samples collected for ELISA analysis measure levels inflammatory markers, tissues examined histologically using hematoxylin-eosin (HE) staining, western blot was conducted evaluate TLR4 NF-κB expression. Relative control rats, model group animals exhibited significant increases markers (IL-1β, IL-6, TNF-α, TGF-β, CRP), as well enhanced p-NF-κB p65 expression, along histopathological changes. Treatment notably reduced protein expression colonic tissue leading decrease damage. Overall, found modulate TLR4/NF-κB pathway, resulting enhancements insulin resistance reduction responses thereby providing protection intestines. demonstrates potential therapeutic effectiveness addressing

Language: Английский

Citations

0